{
}
The global market for synthetic lethality drugs and targets is projected to grow from $1.3 billion in 2023 to over $5.3 billion by 2033, with a CAGR of 15.09%. North America is expected to dominate the market due to advances in genetic science and rising cancer rates, while the Asia-Pacific region is anticipated to experience the fastest growth. Key players include Pfizer, AbbVie, and AstraZeneca, with increasing investments in biotechnology and personalized medicine driving innovation in cancer treatment.
Kailera Therapeutics has appointed Akamine as its new chief legal officer. He previously held the same position at Cerevel Therapeutics until its acquisition by AbbVie in 2024, and has also served as general counsel at AEON Biopharma and in various roles at Allergan prior to its acquisition by Actavis.
AbbVie Inc. focuses on developing therapeutic drugs for various conditions, including rheumatoid arthritis, psoriasis, and HIV. The company's net sales are predominantly from the United States (77.1%), with smaller contributions from countries like Germany (2.3%) and Japan (1.9%).
The global healthcare services market is projected to grow from $8,348.44 billion in 2023 to $8,963.64 billion in 2024, driven by advancements in medical technology, an aging population, and health insurance expansion. By 2028, it is expected to reach $10,908.99 billion, with key trends including telemedicine integration and patient-centered care. Shared medical appointments are gaining traction as a cost-effective model for managing chronic conditions, enhancing patient outcomes through collaborative care.
Pharmaceutical giants like Pfizer and Moderna are profiting immensely from Covid-19 vaccines, with combined profits reaching $65,000 per minute. Despite their financial success, they have largely neglected low-income countries, delivering less than 1% of their vaccine stocks to these regions. The People's Vaccine Alliance highlights the urgent need for equitable vaccine distribution to combat "vaccine apartheid."
AbbVie Inc. shares plummeted after two mid-stage trials of its schizophrenia drug, emraclidine, failed to meet primary goals, showing no statistically significant improvement in symptom severity. This setback poses a challenge to the company's recent $8.7 billion acquisition of Cerevel Therapeutics. AbbVie plans to analyze the trial data to determine future steps.
Teva Pharmaceuticals reported a 13% revenue increase in Q3, reaching $4.3 billion, driven by strong demand for its generics, particularly in the U.S. The company raised its full-year revenue guidance to $16.1-$16.5 billion, bolstered by successful products like Austedo and upcoming biosimilars, including Selarsdi and Simlandi. CEO Richard Francis emphasized a renewed focus on growth strategies to sustain this momentum.
The global regenerative medicine market, valued at USD 31.90 billion in 2023, is projected to grow at a CAGR of 27.06%, reaching USD 349.93 billion by 2033. North America leads the market due to its advanced healthcare infrastructure and increasing demand for personalized medicine, while musculoskeletal conditions are expected to drive the fastest growth. However, high treatment costs and limited insurance coverage pose significant challenges to market expansion.
The intratumor cancer therapies market, valued at $151.5 million in 2022, is projected to grow at a CAGR of 9.9% from 2023 to 2030, driven by advances in immunotherapy and personalized medicine. Monoclonal antibodies are leading the technology segment, while lung cancer remains the primary application area. North America is the dominant market, fueled by rising cancer prevalence and increased awareness of innovative treatment options.
Regeneron Pharmaceuticals' shares dropped nearly 10% as third-quarter sales of Eylea fell short of expectations, raising concerns about future sales amid competition. In contrast, Madrigal Pharmaceuticals reported strong sales of its MASH drug, Rezdiffra, totaling $62 million, significantly exceeding forecasts. UCB's Alzheimer’s drug trial showed promising secondary results despite missing its main goal, while AbbVie announced a partnership with EvolveImmune Therapeutics to develop cancer therapies.
AbbVie Inc.
Companies
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
ynthetic lethality drugs market projected to reach 5.3 billion by 2033
GlaxoSmithKline
AbbVie Inc.
Pfizer Inc.
AstraZeneca
CAN
GBR
FRA
ARE
ITA
JPN
KOR
DEU
MEX
CHN
ZAF
USA
BRA
ESP
IND
Show more
03:52 19.11.2024
kailera therapeutics appoints akamine as new chief legal officer
01:00 14.11.2024
abbvie maintains neutral rating as it focuses on diverse therapeutic drug development
17:02 12.11.2024
global healthcare services market poised for significant growth through 2028
United States Dollar
Community Health Systems, Inc.
UnitedHealth Group Incorporated
CVS Health Corporation
Regeneron Pharmaceuticals, Inc.
Cardinal Health, Inc.
Fresenius Medical Care AG & Co. KGaA
Centene Corporation
Baxter International Inc.
Mayo Clinic
Agilent Technologies, Inc.
Johnson & Johnson
Pfizer Inc.
Cleveland Clinic Global Solutions LLC
McKesson Corporation
Merck & Co., Inc.
Abbott Laboratories
Bristol-Myers Squibb Company
Quest Diagnostics Incorporated
HCA Healthcare, Inc.
Gilead Sciences, Inc.
Kaiser Permanente Group Trust
Cigna Corporation
Stryker Corporation
Tenet Healthcare Corporation
Danaher Corporation
AbbVie Inc.
Boston Scientific Corporation
Molina Healthcare, Inc.
Align Technology, Inc.
AmerisourceBergen Corporation
Laboratory Corporation OF America Holdings
DaVita Inc.
Eli Lilly and Company
Humana Inc.
West Pharmaceutical Services, Inc.
Fresenius Medical Care AG & Co. KGaA
Kaiser Permanente
UnitedHealth Group Incorporated
Tenet Healthcare
HCA Healthcare
Show more
20:40 11.11.2024
pharmaceutical industry scandals and lobbying influence on public health decisions
United States Dollar
Novartis AG
Merck & Co., Inc.
Moderna, Inc.
GlaxoSmithKline
Pfizer Inc.
Takeda
AbbVie Inc.
Bristol Meyers
Sanofi
Hoffmann-La Roche AG
Johnson & Johnson
USA
Jean-François Delfraissy
Christian Perronne
Arnaud Fontanet
Robert Malone
Didier Raoult
Show more
15:20 11.11.2024
abbvie shares drop as schizophrenia drug fails in clinical trials
15:08 11.11.2024
teva reports strong generics demand raises 2024 revenue outlook
United States Dollar
Teva Pharmaceuticals
Viatris Inc.
AbbVie Inc.
Bristol-Myers Squibb Company
Novo Nordisk A/S
Johnson & Johnson
USA
ISR
Richard Francis
AbbVie
Johnson & Johnson
Show more
14:46 07.11.2024
regenerative medicine market poised for rapid growth driven by innovation and demand
United States Dollar
Novartis AG
AbbVie Inc.
Hoffmann-La Roche AG
Pfizer Inc.
Johnson & Johnson
FRA
CHN
ESP
BRA
KOR
IND
ZAF
ITA
CAN
USA
JPN
MEX
GBR
DEU
ARE
AUS
Dr. Samuel Lynch
Pfizer
Lynch
Samuel Lynch
Johnson & Johnson
Show more
00:23 07.11.2024
growth of intratumor cancer therapies market driven by innovative treatments and technologies
United States Dollar
Eli Lilly and Company
AbbVie Inc.
AstraZeneca PLC
Amgen Inc.
Novartis AG
Merck & Co., Inc.
Pfizer Inc.
F. Hoffmann-La Roche Ltd.
Bristol-Myers Squibb Company
Bayer AG
USA
Show more
06:23 04.11.2024
regeneron faces sales uncertainty while madrigal reports strong drug launch results
United States Dollar
Regeneron Pharmaceuticals, Inc.
H. Lundbeck A/S
AbbVie Inc.
PTC Therapeutics, Inc.
UCB SA
USA
Alistair Henry
David Risinger
Joseph Schwartz
Brian Abrahams
Show more
11:06 01.11.2024
Trending
Subcategory
Countries:
Companies:
Currencies:
People: